2776 news items
Page 3 of 100
wu83qetawom3yvt0zcw4pqmzif0q
ELLO
31 May 24
the Company makes from time to time with Securities and Exchange Commission, including its Annual Report on Form 20-F. The forward-looking statements
5wq6ck4ofsvzjn3964rau
ABBV
31 May 24
.Mehta, F. (2016) "Report: economic implications of inflammatory bowel disease and its management." Am
ndvnp6b
NYXH
31 May 24
the heading "Risk Factors" in Nyxoah's most recent Annual Report on Form 20-F filed with the SEC, as well as subsequent filings and reports filed
n1x2ujeyzyd7xtaupw146w10d688sfipuaw9kiqmex0e3
REGN
31 May 24
annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation
oajokugzl9bik6z7on7eidfnhqqa65tdgokti8
ADXN
31 May 24
"Risk Factors" in Addex Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2023, as filed with the SEC on April 18, 2024, the final
nfrej mygeiyxpwq0pqmz01xxgiykn5
REGN
31 May 24
Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake
ooowaf12bw0qt30yyr1mxiiw
NVX
30 May 24
and Exchange Commission ("SEC"), including the Company's Form 20-F. Copies of these filings may be obtained by visiting our Investor Relations website
bbc3 pk7023eq1opjgijx7
CMBM
NARI
SPT
30 May 24
for the quarter. The company also revised its full year 2024 revenue guidance downward $20 million. The Company's Chief Financial Officer ("CFO") Joe Del
dl8qq6bdqyhscwikwydzakc gu7ophqdmhbrey
30 May 24
The compulsory acquisition process of the remaining OreCorp shares completed on May 20, 2024
0pjg09i89fky yj51atsbhuam375fqhqlp2b9qy2vzwdedmylisi6n7
MYGN
QGEN
30 May 24
Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S
eu1icw4topwe7r997ki3e7jeklr8i2m50k23lo2w9tk3wa4v
KDOZF
30 May 24
to the company's filings with the Securities and Exchange Commission. Specifically, readers should read the Company's Annual Report on Form 20-F, filed
0fh4ff4kswevseu5g8je6vy70mqmdcedr8 6059
ADAP
GLPG
30 May 24
Adaptimmune and Lonza), as well as those risks and uncertainties identified in Galapagos' Annual Report on Form 20-F for the year ended 31 December 2023
4pg81 tvf8o8spv1gczckw8lcfqgbax271svk7vb
IMCR
30 May 24
with the Securities and Exchange Commission, including Immunocore's most recent Annual Report on Form 20-F for the year ended December 31, 2021 filed
yg826aov777e8ybe735dlqimpl1jl3bbvneuysjz7m8qc5bhbx1096raj
PLCE
30 May 24
in transforming how plaintiffs access justice. With over 20 years of experience, Max has overseen more than 10,000 investments in legal claims, fostering